ccf-1999-2301 CCJ Paper Report <p>Endotracheal tube and VAP</p> Venn Richard Critical Care 1364-8535 1999 2 2301 http://ccforum.com/paperreport/ccf-1999-2301 10.1186/ccf-1999-2301 <p>Implications of endotracheal tube biofilm for ventilator-associated pneumonia</p> Adair CG Gorman SP Feron BM Byers LM Jones DS Goldsmith CE Moore JE Kerr JR Curran MD Hogg G Webb CH McCarthy GJ Milligan KR Intensive Care Med 1999 25 1072 1076 23 11 1999 1999 Current Science Ltd Antibiotic resistance, microbial biofilm, ventilator-associated pneumonia Interesting Respiratory Sepsis Level III

Comments

This interesting study helps to explain the mechanism behind the association of endotracheal intubation with VAP. The value of routine antibiotic sensitivity testing to biofilm microorganisms is also questioned. In clinical terms, this paper supplies more ammunition for early extubation and the use of noninvasive modes of ventilation (if support is still required) in an attempt to reduce VAP.

Introduction

The endotracheal tube (ET) is a risk factor for ventilator-associated pneumonia (VAP) because host defences are circumvented. Work has shown that microorganisms may cling to the ET and secrete an exopolysaccharide (the biofilm) that encases bacteria, making them relatively resistant to antibiotics. Suctioning, or even the ventilator gas flow, may then uproot segments of biofilm and carry potentially resistant organisms into the lungs.

Aims

To identify whether ET biofilm is associated with VAP (as defined in paper).

Methods

In total, 20 patients with VAP and 20 patients without VAP were studied in two intensive care units (ICUs). Patients with infections appearing within 48 h of intubation were excluded, since these were considered nosocomial in origin. During ventilation, tracheal secretions were sent for bacteriological culture and following extubation, the ET biofilm microbiology was examined. Microorganism genotyping and antibiotic susceptibility testing was undertaken when the same organism was isolated from both ET and tracheal secretions.

Results

Biofilm was identified in all ETs in the study. Highly pathogenic organisms were found in all VAP patient ETs, but in only 30% of control ETs. Pathogenic microorganisms were identified in 85% of tracheal secretions in the VAP group, compared to 20% in the control. However, no matching pairs of organisms were found in the control group, compared to 70% in the VAP group (following genotyping). Organisms identified for matching pairs were Pseudomonas sp, Staphylococcus aureus, Enterococcus faecalis, Candida sp and EGNB (Proteus, Klebsiella and Enterobacter). Minimal inhibitory concentrations for commonly administered antibiotics showed no significant differences between tracheal and ET organisms in planktonic growth mode, but minimal bactericidal concentrations were significantly lower in tracheal isolates when compared to ET isolates in biofilm growth mode.

Discussion

ET biofilm is implicated in the pathogenesis of VAP, and was present in all patients being ventilated in the ICU. Previous work has shown that this biofilm develops within hours of intubation and so it is probable that colonisation of the ET precedes that of the airways. Microorganisms within the biofilm are metabolically inactive, so the usual antibiotic sensitivity testing based on minimal inhibitory concentration (with the isolated organism in suspension in vivo) is inappropriate. Methods to determine sensitivities against these organisms in biofilm growth mode need to be developed.